This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRVL Prevail Therapeutics (PRVL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Prevail Therapeutics Stock (NASDAQ:PRVL) 30 days 90 days 365 days Advanced Chart Get Prevail Therapeutics alerts:Sign Up Key Stats Today's Range$23.00▼$23.0050-Day Range$22.91▼$23.2052-Week Range$9.02▼$23.35VolumeN/AAverage Volume955,800 shsMarket Capitalization$787.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York. Read More Receive PRVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prevail Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRVL Stock News HeadlinesPrevail International On Track to Deliver State-of-the-Art Parirenyatwa FacilitiesJuly 25, 2025 | msn.comI Prevail Announce Fourth Studio Album, Reveal New Single ‘Rain’July 19, 2025 | msn.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for. | Investors Alley (Ad)How I Prevail’s Eric Vanlerberghe Learned to Do Clean VocalsJuly 19, 2025 | msn.comUkraine's Skyeton and UK's Prevail Partners launch joint drone productionJuly 3, 2025 | msn.comPrevail Therapeutics Inc (PRVL) Stock Forums - Investing.comJune 30, 2025 | investing.comI Prevail Announce Split With Co-Vocalist Brian Burkheiser in New StatementMay 16, 2025 | msn.comLeawood-based Prevail launches $100M VC fund, makes first two investmentsApril 9, 2025 | bizjournals.comSee More Headlines PRVL Stock Analysis - Frequently Asked Questions How were Prevail Therapeutics' earnings last quarter? Prevail Therapeutics Inc. (NASDAQ:PRVL) announced its quarterly earnings data on Friday, November, 13th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.09. When did Prevail Therapeutics IPO? Prevail Therapeutics (PRVL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Prevail Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prevail Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Alector (ALEC), Advanced Micro Devices (AMD), Atreca (BCEL) and Homology Medicines (FIXX). Company Calendar Last Earnings11/13/2020Today9/14/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PRVL CIKN/A Webwww.prevailtherapeutics.com Phone917-336-9310FaxN/AEmployees66Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.19 million Net MarginsN/A Pretax MarginN/A Return on Equity-55.57% Return on Assets-48.14% Debt Debt-to-Equity RatioN/A Current Ratio7.56 Quick Ratio7.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book4.74Miscellaneous Outstanding Shares34,246,000Free FloatN/AMarket Cap$787.66 million OptionableNot Optionable Beta1.59 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:PRVL) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prevail Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prevail Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRVL Stock Alerts